Back
Viatris Inc. (VTRS)
PharmaceuticalsVTRS · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$17.44
−0.29%Weekly undervalued picks (like VTRS)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$-3.00
ROE
-2.0%
Gross margin
39.8%
Debt/Equity
1.00x
Revenue growth
8.1%
Viatris Inc. — company intelligence
Earnings surprises
Q2 2026$0.69 vs $0.61 est+12.6%
Q1 2026$0.59 vs $0.51 est+15.2%
Q4 2025$0.57 vs $0.54 est+4.8%
Q3 2025$0.67 vs $0.63 est+5.8%
Analyst consensus · 17 analysts
11 Buy5 Hold1 Sell
Updated Oct 5, 2026
Insider activity · 90 days
2 buys2 sellsnet -6,780 shares
Groothuis Leo FransBuy 2,469 · Sep 30, 2026
SIMMONS DAVID SBuy 2,117 · Sep 30, 2026
Enrietti Andrewother 999 · Aug 15, 2026
Recent SEC filings
8-K — Material event reportOct 8, 2026
4 — Insider transaction reportOct 2, 2026
4 — Insider transaction reportOct 2, 2026
Latest news
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? — Yahoo · 2w ago
3 US Stocks That Could Gain If Buyers Shift Away From India — Yahoo · 3w ago
Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation — Yahoo · 3w ago
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13 — Benzinga · 3w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like VTRS)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.